Imagion Biosystems is pleased to advise that it has now received the full $4.8 million from the exercise of all 96,706,395 listed options (IBXO) which had an expiry date of 26 November 2021 and were exercisable at $0.05.
Executive Chairman and CEO Bob Proulx said, “We are grateful for the support from our option holders and pleased to welcome a quality US based institutional investor to the register. Receiving the maximum funds from the IBXO options has strengthened our cash reserves as we continue towards completion of our MagSense® Phase I study and the development of our platform technology.”
Review the full announcement.
